Cerus Corporation (NASDAQ:CERS) announced today that Chrystal Menard has been appointed chief legal officer, effective December 3, 2012.
“Chrystal is an ideal choice to succeed Howard Ervin as chief legal officer as we look forward to building on the commercial success of the INTERCEPT Blood System," said William 'Obi' Greenman, Cerus' president and CEO. "She has an in-depth knowledge of both Cerus and INTERCEPT, gained during the years she acted as outside counsel to the company. She also brings substantial experience in representing companies in the life science and medical products industry."
Ms. Menard was a partner at Cooley LLP, where she had practiced corporate and securities law from 2000 to 2011. Prior to joining Cerus, Ms. Menard served as senior corporate counsel at Zynga, Inc., where she had been since August 2011. Ms. Menard received her Juris Doctorate from the University of Chicago and her Bachelor of Science in finance and accounting from the University of Colorado, Boulder.
Ms. Menard succeeds Howard Ervin, who will be retiring from his full-time leadership role, but will continue to provide legal support and continuity in a part-time role as vice president, legal affairs.“We greatly appreciate Howard’s continued service to Cerus, and expect a smooth transition within the legal department,” said Mr. Greenman. “Howard has guided Cerus in the legal area since the company's founding in 1991, and his contributions have been instrumental in achieving our success." ABOUT CERUS Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV